In a multicenter, cross-sectional study of 280 blood samples from four European centers, published in Nature Medicine on March 11, 2026, researchers led by Mathias Jucker at the German Center for Neurodegenerative Diseases and the University of Tubingen report that serum p-tau181, the phosphorylated tau protein used in blood tests to flag Alzheimer's disease, was also elevated in people with immunoglobulin light chain (AL) amyloidosis and transthyretin (ATTR) amyloidosis. These are systemic diseases in which misfolded proteins deposit in the heart, kidneys and peripheral nerves rather than the brain. The samples came from clinics in Pavia, Heidelberg, Groningen and Tubingen, and included 97 people with AL amyloidosis, 82 with ATTR amyloidosis, 30 with polyneuropathy from other causes, and 71 controls. The elevation was more pronounced in AL than in ATTR, and largest in patients who also had polyneuropathy, a nerve complication of both diseases. In one 114 person subgroup from Heidelberg where researchers also measured p-tau217, the tau variant now central to several blood tests marketed for Alzheimer's screening, that marker showed a similar rise and distinguished AL and ATTR patients from controls about as well as p-tau181 did. In people carrying hereditary ATTR mutations who had not yet developed symptoms, p-tau181 climbed in step with how close they were, by genetic prediction, to symptom onset. A comparison group mattered here: people with polyneuropathy not caused by amyloidosis did not show the same rise, indicating the effect tracks amyloid deposition specifically rather than nerve damage in general. The authors, whose team previously described a similar tau release from Danish-type cerebral amyloid in mouse brain tissue, wrote that the finding may complicate blood-based presymptomatic AD diagnosis, since a positive p-tau result cannot on its own distinguish cerebral amyloid from amyloid building up elsewhere in the body.